CTC
MRVI icon

Central Trust Company’s Maravai LifeSciences MRVI Stock Holding History

Central Trust Company’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$221 – 1468
2025
Q1 		$221 Buy
+100
New +$395 ﹤0.01% 1426

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Central Trust Company's MRVI Position: Q2 2025 in Review

Central Trust Company sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 100 shares — an estimated $221 sold.

Central Trust Company first reported a position in MRVI in Q1 2025 and held it in 1 quarter. The position peaked at $221 in Q1 2025. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Central Trust Company reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Central Trust Company sold 100 Maravai LifeSciences shares in Q2 2025, an estimated $221.
  • Central Trust Company first reported a position in Maravai LifeSciences in Q1 2025 and held it in 1 quarter.
  • Central Trust Company's Maravai LifeSciences position peaked at $221 in Q1 2025.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Central Trust Company's 13F filing for Q2 2025, filed 7 Aug 2025.